Peptides for Recovery After Surgery: What Is Used, and When to Start

The phases overlap, and deeper tissues run slower than skin: a tendon or ligament remodels for many months. Your surgeon's instructions about load and wound care are built around this program, which is why "when can I start" is really "which phase am I in."

Tendon, ligament, cartilage and the middle of a large flap are poorly vascularized, and the proliferative phase depends on new capillaries growing into the wound. This is why BPC-157 and TB-500 are described in animal work around angiogenesis, and also why both are inappropriate after cancer surgery: the signal that supplies a healing tendon can supply a tumor.

The inflammatory phase clears the wound and calls in the repair cells; the problem is inflammation that fails to switch off. A wound that stays hot, swollen and painful past the first week is either infected, a surgical question, or stuck in a loop that keeps the proliferative phase from starting. KPV is raised for the second, never as a substitute for ruling out the first.

Adult tissue repairs by scar, not regeneration, and remodelling decides whether that scar is flat, pliable and strong or thick, tight and weak. GHK-Cu has the deepest literature on collagen synthesis and the enzymes that remodel it, which is why it is raised when scar quality is the question. Separately, major operations, anesthetics, blood loss and the stress response depress cellular immunity for days to weeks, which is part of why postoperative infections cluster then. Someone run down and catching everything through a long recovery is the situation in which thymosin alpha-1 is raised; it acts on a different system and carries its own cautions.

A 15-amino-acid fragment of a protein found in human gastric juice. Animal research describes it promoting new blood-vessel formation through the VEGF receptor pathway and the nitric-oxide system, and upregulating growth-hormone receptor expression in tendon fibroblasts. Separate work describes protection of the gastrointestinal lining, which is why it comes up specifically after abdominal surgery. See is BPC-157 safe.

The surgical models are the relevant part. A 2003 paper in the Journal of Orthopaedic Research reported faster healing of a transected and repaired rat Achilles tendon, and a 2006 paper in the same journal reported the same for a transected rat quadriceps. A 2013 paper in the Journal of Physiology and Pharmacology reported healing of a colon-to-colon anastomosis in rats given BPC-157 that did not occur in controls, and a 2016 paper in the World Journal of Gastroenterology reported better anastomotic strength after esophagogastric anastomosis in rats. A 2009 paper in the Journal of Physiology and Pharmacology described less clot formation at an abdominal aortic anastomosis in rats: BPC-157 is described as acting on vessels and clotting, which is exactly why the surgeon has to weigh it against an anticoagulant. Human data: early-phase work in inflammatory bowel disease, none in surgical recovery. There are no randomized human trials of BPC-157 after surgery.

Related to thymosin beta-4, one of the most abundant proteins inside human cells. It binds actin, the protein that allows a cell to move, which is the basis of its described effect on cell migration into damaged tissue. Published work also reports new vessel formation, reduced inflammatory mediators, and less scar formation in some injury models.

A 1999 paper in the Journal of Investigative Dermatology reported faster full-thickness wound closure in rats, and a 2003 paper in Wound Repair and Regeneration extended that to diabetic and aged mice, the two populations in which surgical wounds heal worst. A 2026 paper in Joint Diseases and Related Surgery compared BPC-157, TB-500 and the combination in rats after Achilles tendon transection and repair, dosed for four weeks postoperatively: the TB-500 group reached a significantly higher load to failure than controls, both peptides were associated with better histological scores, and the combination did not add to either alone. Human data exists, which is unusual here: a 2010 randomized placebo-controlled safety study of intravenous thymosin beta-4 in healthy volunteers and a 2012 paper on dermal healing in patients with chronic wounds, both in the Annals of the New York Academy of Sciences. That is chronic-wound and safety data, not surgical recovery data. TB-500 is prohibited at all times under the WADA list.

The combination vial exists because the two are prescribed together far more often than apart: BPC-157 is described around angiogenesis and gastrointestinal protection, TB-500 around actin-driven cell migration and matrix remodelling. It is the default conversation for a tendon, ligament or muscle repair once the surgeon has agreed. Worth knowing before you ask for BPC-157 + TB-500: the only surgical head-to-head, the 2026 rat tendon study, did not find the combination outperformed either alone. The rationale for pairing them is mechanistic breadth, not a demonstrated additive effect.

A copper-binding tripeptide that occurs naturally in plasma and declines with age. It delivers copper where copper-dependent enzymes need it, and research describes increased synthesis of collagen, elastin and proteoglycans, along with a shift in the balance between the enzymes that break tissue down and the inhibitors that stop them. It has the deepest literature of the repair peptides, including human skin work.

A 1988 paper in FEBS Letters reported increased collagen synthesis in cultured fibroblasts, a 1993 paper in the Journal of Clinical Investigation reported increased connective-tissue accumulation in rat wounds, and a 1999 paper in the Journal of Investigative Dermatology described modulation of matrix metalloproteinases in wounds. Closest to this page, a 2015 paper in the Journal of Orthopaedic Research injected GHK-Cu into the knee of rats after anterior cruciate ligament reconstruction: at six weeks treated animals had less knee laxity and stiffer grafts than saline controls, but the difference was gone at twelve weeks once treatment stopped. The one human study in a procedural setting, a 2006 paper in the Archives of Facial Plastic Surgery, applied topical copper tripeptide after laser resurfacing; that is a topical product on a skin procedure, not injectable GHK-Cu after an operation. Not for anyone with Wilson's disease or a copper-handling disorder. See what is GHK-Cu.

The final three amino acids of alpha-MSH, described as interfering with inflammatory signalling inside the cell including the NF-kB and MAPK pathways, reducing cytokines such as TNF-alpha and IL-6. Inflammation that will not resolve is a common reason a repair phase stalls.

The literature is gut and cell work: a 2008 paper in Gastroenterology reported that KPV taken up through the PepT1 transporter reduced intestinal inflammation in mice, a 2008 paper in Inflammatory Bowel Diseases reported the same in murine colitis, and a 2012 paper in the International Journal of Physiology, Pathophysiology and Pharmacology described the mechanism in human bronchial epithelial cells. None of it is postoperative, and there are no randomized human trials of KPV. It is raised once the surgeon has confirmed the wound is not infected and the picture is inflammation that is not settling, usually within KLOW or FORTIFY. See what is KPV.

KLOW combines GHK-Cu, KPV, BPC-157 and TB-500 in one vial, for a recovery with two problems at once: tissue that needs to rebuild and inflammation that is slowing it. GLOW is GHK-Cu, BPC-157 and TB-500 without KPV, and is the conversation after a skin or cosmetic procedure when scar and skin quality matter alongside repair. Every caution that applies to a component applies to the blend: the copper caution for GHK-Cu in both KLOW and GLOW, and the cancer-history caution for the three pro-angiogenic peptides.

A 28-amino-acid peptide produced naturally by the thymus, described as modulating immune function through effects on T-cell maturation, dendritic cell signalling and Toll-like receptor pathways. It is approved in some countries for hepatitis B and as a vaccine adjuvant. It is raised when someone is run down through a long recovery, and it is the one that needs specialist input if you have autoimmune disease or are on immunosuppressive therapy. See peptides for immune support.

Thymosin alpha-1 is the one molecule here with a real randomized human literature: a 1998 randomized controlled trial in chronic hepatitis B in Hepatology, covered by a 2026 Cochrane review; a 2013 multicenter randomized trial in severe sepsis in Critical Care; and the larger placebo-controlled phase 3 sepsis trial in the BMJ in 2025, which did not meet its primary endpoint. In a surgical population, a 2024 paper in Biotechnology and Genetic Engineering Reviews reported a randomized study of 400 patients undergoing colorectal cancer resection at a single Chinese center, in which those given thymalfasin alongside chemotherapy had a lower incidence of perioperative infection and higher immune-function indices than chemotherapy alone. One center, one cancer, one chemotherapy regimen: it is the closest the literature comes, and it is not evidence for thymosin alpha-1 in general surgical recovery.

FORTIFY pairs thymosin alpha-1 with BPC-157, KPV and LL-37. LL-37 is the human cathelicidin, with randomized placebo-controlled human data of its own: a 2014 paper in Wound Repair and Regeneration and a 2021 multicenter follow-up reported topical LL-37 in hard-to-heal venous leg ulcers, a topical product on chronic ulcers rather than an injectable after surgery. FORTIFY is the conversation when the problem is both a slow repair and repeated infections, and the autoimmune and immunosuppression cautions for thymosin alpha-1 apply to FORTIFY in full.

ARA-290 is an 11-amino-acid peptide derived from erythropoietin that binds the innate repair receptor without stimulating red blood cell production. It is not a repair peptide; it is raised for nerve pain that persists after the wound has healed. Small randomized trials in sarcoidosis-associated small-fiber neuropathy, in Molecular Medicine in 2012 and 2013, and a 2015 paper in type 2 diabetes described improvements in neuropathic symptoms and corneal nerve fiber density. None involved post-surgical pain, which needs a diagnosis first: a trapped nerve, a neuroma and a suture through a nerve are surgical problems.

From 2023 until April 2026, BPC-157, TB-500, KPV and injectable GHK-Cu sat in Category 2 of the FDA's interim 503A bulk drug substances list, the category for nominated substances the agency considered to raise significant safety risks. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2 because their nominations had been withdrawn, effective seven days later, and stated that removal "does not, by itself, place these substances on the 503A bulks list or into Category 1." The FDA's safety-risk page, updated 22 April 2026, now lists BPC-157, thymosin beta-4 fragment and GHK-Cu among substances nominated but withdrawn, and its active 503A Category 2 table contains six substances, none a peptide on this page. On the category list updated 14 May 2026, BPC-157, TB-500, KPV and thymosin alpha-1 appear in no category; cibinetide, the drug name for ARA-290, sits in Category 3, nominated without adequate support, which is a statement about the paperwork rather than a safety finding.

The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and on the first day took up BPC-157, KPV and TB-500, each as the free base and the acetate. In each briefing document the FDA's own reviewers concluded that "a balancing of the criteria weighs against" the substance being placed on the list. The committee voted the other way: 8 yes, 6 no and one abstention to recommend adding BPC-157 to the 503A Bulks List, and by the same margin KPV and TB-500. Across the two days the committee recommended six of the seven peptides on its agenda.

A committee vote is a recommendation, not a decision. The FDA issues its own determination after weighing the vote, public comment and its scientific review, and adding a substance to the Bulks List requires notice-and-comment rulemaking. As of September 2026 that determination is pending for all three.

Injectable GHK-Cu was not on the July agenda. After the April withdrawal, one nominator clarified on 5 May 2026 that it meant to withdraw only the injectable route, and on 14 May 2026 the FDA added "GHK-Cu (except for injectable routes of administration)" back to Category 1, substances under evaluation, while stating that it intends to consult the committee on GHK-Cu before the end of February 2027. Injectable GHK-Cu, the form in GLOW, KLOW and the standalone product, is therefore where BPC-157 and TB-500 were between April and July: no longer flagged, not yet reviewed for the positive list.

On 4 December 2024 the same committee voted 4 in favor and 17 against placing thymosin alpha-1 on the 503A Bulks List; the uses reviewed were hepatitis B and C, HIV, COVID-19, depressed response to vaccination and adjuvant to flu vaccine. That vote is a recommendation; the FDA has not issued a final determination, and thymosin alpha-1 appears in no category on the 14 May 2026 list. It remains legal to prescribe and compound. Its approvals for hepatitis B and as a vaccine adjuvant are in other countries; it is not FDA approved in the United States for any indication. Nor is anything else on this page: compounded medications are never FDA-approved products, and it is legal to prescribe and dispense them with a valid prescription.

The WADA Prohibited List in force is the 2026 list. It names BPC-157 explicitly under section S0, non-approved substances, which prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use. The same list names "Thymosin-ß4 and its derivatives e.g. TB-500" under S2, growth factors and growth factor modulators, also prohibited at all times. KPV and injectable GHK-Cu fall under the same S0 logic. A tested athlete recovering from surgery should check with their anti-doping organization before starting anything on this page and say so on the intake.

Spreading redness, warmth, discharge, a new smell, increasing pain after day three, or fever means a wound infection until proven otherwise: an examination, a swab, possibly an antibiotic, possibly a return to theatre. A peptide layered over an undiagnosed infection delays the treatment that would help, and thymosin alpha-1 specifically should not be started into an active surgical-site infection. A re-tear, a leaking anastomosis, a loosened fixation or a failing flap also presents as slow recovery, and is a surgical problem.

Many people leave hospital on an anticoagulant or antiplatelet for weeks after orthopaedic, cardiac or vascular surgery. BPC-157, TB-500 and GHK-Cu are all described as acting on vessels, and BPC-157 in rat work on clot formation at an anastomosis. The physician will want to know exactly what you are on and for how long, and the surgeon has to agree.

Collagen synthesis needs protein, vitamin C, zinc and adequate calories, and postoperative anemia is common and slows everything. A ferritin, a blood count and a look at what you are eating come before any peptide; this is the commonest reason a recovery is slow, and it is fixed with food and iron, not an injection. Uncontrolled glucose impairs every phase of healing, an untreated thyroid problem slows recovery generally, and at-home blood testing covers both. Nicotine constricts the small vessels a healing wound depends on, and no peptide compensates for it.

Most people notice nothing beyond the injection itself. Some describe background soreness and swelling settling, which is hard to separate from the recovery already underway. Absence of any change in this window is normal.

This is where tissue-level change would be expected if it occurs, based on the animal timelines, and it overlaps with the point at which rehabilitation is progressing anyway. Prescribers describe it as the period where people report the repair feeling more robust under load. Whether that is the peptide, the physiotherapy or time is not something anyone can separate for an individual.

Scars take months to a year to settle regardless. GHK-Cu is the molecule raised for this phase, and any effect on scar quality would be judged at three to six months, not weeks; photographs at intervals are the only honest way to assess it. Treatment is long-term on 28-day refills, one vial per fill; your physician reviews you at each refill and decides whether to continue, change the product, or stop. There is no withdrawal and no rebound described in the literature for any of these molecules.